Lupin Secures U.S. FDA Approval For Pitolisant Tablets

Lupin received final U.S. FDA approval for Pitolisant Tablets 4.45 mg and 17.8 mg, bioequivalent to Wakix for approved indications. The approval adds a complex generic to Lupin’s U.S. portfolio, although the release provides no launch timing, market-size or commercial details.